HUE046154T2 - A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében - Google Patents

A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében

Info

Publication number
HUE046154T2
HUE046154T2 HUE12790904A HUE12790904A HUE046154T2 HU E046154 T2 HUE046154 T2 HU E046154T2 HU E12790904 A HUE12790904 A HU E12790904A HU E12790904 A HUE12790904 A HU E12790904A HU E046154 T2 HUE046154 T2 HU E046154T2
Authority
HU
Hungary
Prior art keywords
dims0
nucleotides
treatment
ulcerative colitis
chronic active
Prior art date
Application number
HUE12790904A
Other languages
English (en)
Hungarian (hu)
Inventor
Charlotte Admyre
Arezou Zargari
Stein Oliver Von
Stein Petra Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of HUE046154T2 publication Critical patent/HUE046154T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE12790904A 2011-11-25 2012-11-23 A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében HUE046154T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06

Publications (1)

Publication Number Publication Date
HUE046154T2 true HUE046154T2 (hu) 2020-02-28

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12790904A HUE046154T2 (hu) 2011-11-25 2012-11-23 A DIMS0-150 nukleotid alkalmazása a krónikus aktív fekélyes vastagbélgyulladás kezelésében

Country Status (16)

Country Link
US (3) US9492516B2 (enExample)
EP (3) EP2596806A1 (enExample)
JP (2) JP6193248B2 (enExample)
CA (1) CA2892203C (enExample)
CY (1) CY1122089T1 (enExample)
DK (1) DK2782602T3 (enExample)
ES (1) ES2745677T3 (enExample)
HR (1) HRP20191723T1 (enExample)
HU (1) HUE046154T2 (enExample)
LT (1) LT2782602T (enExample)
PL (1) PL2782602T3 (enExample)
PT (1) PT2782602T (enExample)
RS (1) RS59358B1 (enExample)
SI (1) SI2782602T1 (enExample)
SM (1) SMT201900527T1 (enExample)
WO (1) WO2013076262A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881808C (en) * 2013-07-05 2021-08-17 Sony Corporation Transmission apparatus, transmission method, reception apparatus, and reception method
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201807312D0 (en) 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JP2008526249A (ja) 2005-01-13 2008-07-24 プロジェニカ・バイオファーマ・エス・アー ｉｎｖｉｔｒｏ遺伝子タイピングのための方法および製品
EP1892293A4 (en) 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
PT2179737E (pt) 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
ES2560782T3 (es) * 2008-11-04 2016-02-22 Index Pharmaceuticals Ab Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC

Also Published As

Publication number Publication date
EP2596806A1 (en) 2013-05-29
CA2892203C (en) 2021-11-16
JP2017061508A (ja) 2017-03-30
US20170014442A1 (en) 2017-01-19
JP6318221B2 (ja) 2018-04-25
LT2782602T (lt) 2019-10-10
WO2013076262A1 (en) 2013-05-30
US9492516B2 (en) 2016-11-15
EP2782602B1 (en) 2019-06-26
JP2015504438A (ja) 2015-02-12
PT2782602T (pt) 2019-10-14
US20180015117A1 (en) 2018-01-18
SI2782602T1 (sl) 2019-11-29
ES2745677T3 (es) 2020-03-03
DK2782602T3 (da) 2019-09-30
RS59358B1 (sr) 2019-11-29
EP3556403A1 (en) 2019-10-23
EP2782602A1 (en) 2014-10-01
US9795627B2 (en) 2017-10-24
PL2782602T3 (pl) 2019-12-31
SMT201900527T1 (it) 2019-11-13
US20150004187A1 (en) 2015-01-01
CA2892203A1 (en) 2013-05-30
CY1122089T1 (el) 2020-11-25
JP6193248B2 (ja) 2017-09-06
HRP20191723T1 (hr) 2019-12-13

Similar Documents

Publication Publication Date Title
PL2673237T5 (pl) Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
BR112013032887A2 (pt) cateter
EP2663304A4 (en) COMBINATION THERAPY
BR112013024052A2 (pt) artigo absorvente
HUE040564T2 (hu) Kombinációs ischemia terápia
EP2661169A4 (en) SELF-DRIVEN FUSIONING
DK2782602T3 (da) Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
EP2776441A4 (en) TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
FI20115876A0 (fi) Yhdistelmähoito
BR112014000003A2 (pt) artigo absorvente
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
EP2770969A4 (en) Bed chair
IL229081A0 (en) Isoxazolines as therapeutic agents
FI20115640A0 (fi) Yhdistelmähoito
IL237150A0 (en) Treatment regimens
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
FI20116093L (fi) Vettä käsittelevä laitos
IL228729A0 (en) Treatment regimens
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
EP2688566A4 (en) THERAPEUTIC AGENTS AGAINST CANCER
DK2694056T3 (da) Terapeutisk behandling